Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Bitmine plans to issue $300 million perpetual preferred shares modeled after Strategy, with an annual dividend yield of 9.5%

Bitmine plans to issue $300 million perpetual preferred shares modeled after Strategy, with an annual dividend yield of 9.5%

BlockBeatsBlockBeats2026/06/03 23:26
Show original

BlockBeats news, on June 4, according to filings submitted to the US SEC, Bitcoin mining company Bitmine Immersion Technologies announced the issuance of 3 million Series A perpetual preferred shares with an annual yield of 9.50%, each with a par value of $100, with an expected total fundraising amount of $300 million. According to the issuance terms, the preferred shares will have an initial liquidation preference of $100 per share, which may be adjusted in the future according to relevant regulations, but will not fall below $100.


The preferred shares will pay a cumulative dividend at an annualized rate of 9.5%, distributed weekly in cash. Even if the company does not declare dividends or temporarily lacks distributable funds, dividends will continue to accumulate. Bitmine stated that, in the future, the frequency of distributions may be increased depending on circumstances, providing investors with a stable source of cash returns.


In addition, the company holds an early redemption right. Within 18 months after the issuance, Bitmine may redeem the preferred shares at 110% of par value; during the period from 18 months to 3 years, the redemption price is 105% of par value; after 3 years, the shares can be redeemed at 100% of par value. All redemptions will require the payment of any accumulated unpaid dividends. If the number of outstanding preferred shares falls below 25% of the total issued, or if certain tax events occur, the company also has the right to redeem all remaining preferred shares.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data

On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)

路透社•2026/10/08 18:26